Unknown

Dataset Information

0

Advancements in PARP1 Targeted Nuclear Imaging and Theranostic Probes.


ABSTRACT: The central paradigm of novel therapeutic approaches in cancer therapy is identifying and targeting molecular biomarkers. One such target is the nuclear DNA repair enzyme Poly-(ADP ribose) polymerase 1 (PARP1). Sensitivity to PARP inhibition in certain cancers such as gBRCAmut breast and ovarian cancers has led to its exploitation as a target. The overexpression of PARP1 in several types of cancer further evoked interest in its use as an imaging target. While PARP1-targeted inhibitors have fast developed and approved in this past decade, determination of PARP1 expression might help to predict the response to PARP inhibitor treatment. This has the potential of improving prognosis and moving towards tailored therapy options and/or dosages. This review summarizes the recent pre-clinical advancements in imaging and theranostic PARP1 targeted tracers. To assess PARP1 levels, several imaging probes with fluorescent or beta/gamma emitting radionuclides have been proposed and three have advanced to ongoing clinical evaluation. Apart from its diagnostic value in detection of primary tumors as well as metastases, this shall also help in delivering therapeutic radionuclides to PARP1 overexpressing tumors. Henceforth nuclear medicine has now advanced towards conjugating theranostic radionuclides to PARP1 inhibitors. This paves the way for a future of PARP1-targeted theranostics and personalized therapy.

SUBMITTER: Ambur Sankaranarayanan R 

PROVIDER: S-EPMC7408801 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Advancements in PARP1 Targeted Nuclear Imaging and Theranostic Probes.

Ambur Sankaranarayanan Ramya R   Kossatz Susanne S   Weber Wolfgang W   Beheshti Mohsen M   Morgenroth Agnieszka A   Mottaghy Felix M FM  

Journal of clinical medicine 20200706 7


The central paradigm of novel therapeutic approaches in cancer therapy is identifying and targeting molecular biomarkers. One such target is the nuclear DNA repair enzyme Poly-(ADP ribose) polymerase 1 (PARP1). Sensitivity to PARP inhibition in certain cancers such as gBRCA<sup>mut</sup> breast and ovarian cancers has led to its exploitation as a target. The overexpression of PARP1 in several types of cancer further evoked interest in its use as an imaging target. While PARP1-targeted inhibitors  ...[more]

Similar Datasets

| S-EPMC5464824 | biostudies-other
| S-EPMC8909184 | biostudies-literature
| S-EPMC4140536 | biostudies-literature
| S-EPMC5923234 | biostudies-literature
| S-EPMC2867879 | biostudies-other
| S-EPMC2702272 | biostudies-literature
| S-EPMC5481817 | biostudies-literature
| S-EPMC6096382 | biostudies-literature
| S-EPMC3203639 | biostudies-literature
| S-EPMC2909298 | biostudies-other